SCHEMBL22834740

SCHEMBL22834740

COc1cnc2c(NC(=O)O)cnn2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.43
IRAK4 Q9NWZ3 6/20 0.43
ACVR2A P27037 1/20 0.43
TGFBR2 P37173 1/20 0.43
PDE2A O00408 5/20 0.43
KDR P35968 5/20 0.39
IRAK1 P51617 2/20 0.38
FLT1 P17948 2/20 0.38
FLT4 P35916 2/20 0.38
PLK4 O00444 1/20 0.38
AURKA O14965 1/20 0.38
DYRK3 O43781 1/20 0.38
MAP4K4 O95819 1/20 0.38
NTRK1 P04629 1/20 0.38
INSR P06213 1/20 0.38
CDK1 P06493 1/20 0.38
FGFR1 P11362 1/20 0.38
CDK2 P24941 1/20 0.38
MARK3 P27448 1/20 0.38
FLT3 P36888 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22843003 0.83 IRAK4 (0.40) HSD11B1IRAK4ACVR2ATGFBR2PDE2A
SCHEMBL359148 0.79 HSD11B1 (0.52) HSD11B1IRAK4ACVR2ATGFBR2PDE2A
SCHEMBL22834990 0.78 ATR (0.41) IRAK4
SCHEMBL22836684 0.78 POLB (0.40) IRAK4PDE2A
SCHEMBL22835083 0.75 PDE2A (0.34) PDE2A
SCHEMBL25791708 0.75 TGFBR2 (0.51) HSD11B1IRAK4ACVR2ATGFBR2PDE2A
SCHEMBL22836536 0.74 IRAK4 (0.40) IRAK4PDE2A
SCHEMBL22834641 0.74 IRAK4 (0.34) IRAK4PDE2A
SCHEMBL23728470 0.72 ALDH1A1 (0.54) HSD11B1IRAK4PDE2A
SCHEMBL29585849 0.70 EPHB3 (0.56) IRAK4EPHB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230087118-A1 IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE BIOGEN MA INC. 2023-03-23 US disclosed
EP-3990454-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE Biogen MA Inc. (US) 2022-05-04 EP disclosed
WO-2020263980-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE BIOGEN MA INC. (US) 2020-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230087118-A1 IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE IRAK4, IRAK2, IRAK1 HSD11B1 3580/4885IRAK4 1/4885ACVR2A 821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.